Emerging from the UK, retatrutide, a innovative molecule, is generating considerable interest within the medical community regarding its promise for physique control . This dual GIP and GLP-1 agent agonist seems to provide a significant advantage over established therapies, showing promising results in initial clinical studies . Researchers think i